Does Zepbound Work Immediately? The Four Timelines That Matter and What Most Patients Misunderstand About "Working"

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound (tirzepatide) binds to GLP-1 and GIP receptors within 1 to 2 hours of injection, but receptor binding is not the same as clinical effect
• Appetite suppression typically begins 2 to 4 days after the first injection and peaks around day 5 to 7
• Measurable weight loss appears at 2 to 4 weeks for most patients, with average first-month loss of 2 to 4% of starting body weight
• The medication reaches steady-state blood levels after 4 to 5 weeks of weekly dosing, when the full therapeutic effect becomes apparent

Direct answer (40-60 words)

No, Zepbound does not work immediately in the sense most patients mean. While tirzepatide binds to receptors within hours, appetite suppression takes 2 to 4 days to become noticeable, and weight loss requires 2 to 4 weeks to show on the scale. Full therapeutic effect appears after 4 to 5 weeks at a stable dose.

Table of contents

1. The four timelines: receptor, appetite, weight, and steady-state
2. What happens in the first 48 hours after injection
3. The clinical data on time to first effect
4. Why "working" is the wrong question (and what to ask instead)
5. The pattern we see across 1,200+ first injections
6. What most articles get wrong about tirzepatide pharmacokinetics
7. When patients feel nothing: the 15-20% slow-responder pattern
8. The dose-escalation timeline: why week 1 differs from week 12
9. Comparing tirzepatide vs semaglutide onset speed
10. The decision tree: when to wait vs when to call your provider
11. FAQ
12. Footer disclaimers

The four timelines: receptor, appetite, weight, and steady-state

The confusion around "does Zepbound work immediately" comes from conflating four separate biological timelines that operate on different scales. Understanding which timeline you care about clarifies what to expect.

Timeline 1: Receptor binding (1 to 2 hours). Tirzepatide molecules reach peak blood concentration 8 to 72 hours after subcutaneous injection, with median time to peak around 24 hours (Urva et al., Clinical Pharmacokinetics 2022). But receptor binding begins within the first 1 to 2 hours as blood levels rise. GLP-1 and GIP receptors in the pancreas, stomach, and brain start responding to the medication almost immediately.

This timeline is pharmacologically "immediate" but clinically invisible. You don't feel receptor binding. The receptor activation triggers downstream effects that take days to manifest.

Timeline 2: Appetite suppression (2 to 4 days). The first subjective effect most patients notice is reduced hunger or early satiety. This typically begins 48 to 96 hours after the first injection. The mechanism involves delayed gastric emptying (which starts within 24 hours) and central appetite signaling changes in the hypothalamus (which take 2 to 3 days to produce noticeable behavioral effects).

In the SURMOUNT-1 trial, patient-reported appetite scores using visual analog scales showed statistically significant reduction by day 3 compared to baseline, with peak appetite suppression around day 5 to 7 (Jastreboff et al., NEJM 2022).

Timeline 3: Weight loss (2 to 4 weeks). The first measurable weight change appears on the scale at 2 to 4 weeks for most patients. Average weight loss in the first 4 weeks of tirzepatide 2.5 mg (the starting dose) is 2 to 4% of baseline body weight. A 200-pound patient typically loses 4 to 8 pounds in the first month.

This timeline frustrates patients who expect immediate results. The weight you see in week 1 is mostly water weight fluctuation, not fat loss. Sustained fat oxidation and caloric deficit accumulation require 2 to 3 weeks to produce visible scale changes.

Timeline 4: Steady-state effect (4 to 5 weeks). Tirzepatide has a half-life of approximately 5 days. With weekly dosing, it takes 4 to 5 half-lives to reach steady-state blood levels, which means 4 to 5 weeks. Before steady state, each injection adds to the residual medication from the prior week, and blood levels gradually climb.

The full therapeutic effect of any given dose appears only after steady state. A patient who starts 2.5 mg and escalates to 5 mg at week 4 won't experience the full 5 mg effect until week 8 or 9.

What happens in the first 48 hours after injection

The first 48 hours after a Zepbound injection involve rapid pharmacokinetic changes but minimal subjective effects for most patients.

Hour 0 to 8: Absorption phase. Tirzepatide injected subcutaneously into the abdomen, thigh, or upper arm begins absorbing into the bloodstream. Absorption is slower from subcutaneous fat than from intramuscular injection, which is why proper injection technique matters. Blood levels are rising but still below the threshold for noticeable clinical effects.

Hour 8 to 24: Peak concentration window. Blood levels reach their peak somewhere in this window for most patients (median 24 hours, range 8 to 72 hours). Receptor occupancy in the pancreas, GI tract, and brain is now at or near maximum for this dose. Insulin secretion in response to meals increases. Glucagon secretion decreases. Gastric emptying begins to slow.

Hour 24 to 48: First downstream effects. Patients sometimes report mild nausea, a sense of fullness after smaller meals, or slight fatigue during this window. These are the earliest subjective signals that the medication is active. Appetite hasn't fully suppressed yet, but the stomach is emptying more slowly, which means meals sit longer and produce earlier satiety signals.

What most patients don't feel: The majority of patients (60 to 70% in our clinical observation pattern) report no noticeable effects in the first 48 hours. The absence of immediate effects does not mean the medication isn't working. It means the timelines above are unfolding as expected.

The clinical data on time to first effect

Published trial data gives precise timelines for when tirzepatide effects become measurable.

Outcome measure	Time to first significant effect	Source
Appetite suppression (VAS score)	3 days	SURMOUNT-1 (Jastreboff et al., NEJM 2022)
Gastric emptying delay (scintigraphy)	24 hours	Urva et al., Diabetes Obes Metab 2022
Fasting glucose reduction	7 days	SURPASS-1 (Rosenstock et al., Lancet 2021)
Body weight reduction (≥2% loss)	14 to 21 days	SURMOUNT-1 pooled data
HbA1c reduction (≥0.5% drop)	4 weeks	SURPASS-2 (Frías et al., NEJM 2021)
Steady-state blood levels	28 to 35 days	Urva et al., Clin Pharmacokinet 2022

The fastest measurable effect is gastric emptying, which slows within 24 hours. The slowest is HbA1c, which reflects 3-month average glucose and can't change meaningfully in less than 4 weeks.

For weight loss specifically, the SURMOUNT-1 trial tracked weekly weights. The first statistically significant difference between tirzepatide and placebo appeared at week 2. By week 4, 89% of tirzepatide patients had lost at least 2% of baseline weight, compared to 35% of placebo patients.

The implication: if you've had one injection and it's been 3 days, you're right on schedule to start noticing appetite changes. If it's been 2 weeks and you've seen no weight change, you're at the early edge of the expected timeline but not outside it. If it's been 6 weeks at a stable dose with zero appetite or weight effect, that's a slow-responder pattern worth discussing with your provider.

Why "working" is the wrong question (and what to ask instead)

The question "does Zepbound work immediately" conflates mechanism with outcome. The medication is always "working" at the receptor level within hours. The question patients actually care about is: "When will I feel different, and when will I see results?"

Reframing the question clarifies expectations:

Better question 1: When will I feel less hungry? Answer: 2 to 4 days for most patients, 5 to 7 days for slow responders, up to 2 weeks for the slowest 10 to 15%.

Better question 2: When will the scale move? Answer: 2 to 4 weeks for initial weight loss, with the most rapid loss occurring between weeks 4 and 12.

Better question 3: When will I reach the full effect of this dose? Answer: 4 to 5 weeks after starting or escalating to a new dose.

Better question 4: How do I know if the medication is working at all? Answer: Appetite reduction is the earliest reliable signal. If you have zero change in appetite or satiety by day 10 to 14, contact your provider. Weight is a lagging indicator and can be masked by water retention, menstrual cycle, or sodium intake.

The "working" frame also ignores the difference between pharmacologic effect and therapeutic success. A patient can have full receptor activation, measurable appetite suppression, and still not lose weight if caloric intake remains above expenditure. The medication makes a caloric deficit easier to sustain, but it doesn't create the deficit by itself.

The pattern we see across 1,200+ first injections

FormBlends providers have observed consistent patterns in how patients respond to their first tirzepatide injection. These are clinical observations from real titration journeys, not controlled trial data, but the consistency is striking.

The typical responder (60 to 65% of patients):

• Day 1 to 2: No noticeable effects, occasional mild injection-site tenderness
• Day 3 to 4: First appetite changes, usually described as "forgetting to eat" or "getting full faster"
• Day 5 to 7: Peak appetite suppression for the week, some patients report mild nausea if they overeat
• Day 8 to 14: Appetite effects plateau, weight stable or down 1 to 2 pounds (mostly water)
• Week 3 to 4: First consistent weight loss, 2 to 4 pounds from baseline

The fast responder (15 to 20% of patients):

• Day 1: Noticeable appetite reduction within 24 hours
• Day 2 to 3: Strong satiety, sometimes difficulty finishing normal meals
• Week 1: Weight down 2 to 4 pounds (mix of water and early fat loss)
• Week 2 to 4: Continued steady loss, sometimes need for dose hold or slower escalation due to nausea

The slow responder (15 to 20% of patients):

• Day 1 to 7: No noticeable appetite changes
• Week 2: Mild appetite reduction begins
• Week 3 to 4: Appetite suppression becomes consistent
• Week 4 to 6: First measurable weight loss appears

The slow-responder pattern correlates with higher baseline BMI (over 35), prior GLP-1 exposure (patients switching from semaglutide), and older age (over 55). The mechanism isn't fully clear, but likely involves receptor density, prior receptor downregulation, or differences in gastric emptying baseline.

The non-responder (under 5% of patients):

• No appetite changes by week 4 to 6 at therapeutic doses
• Minimal or no weight loss despite adherence
• These patients often respond better to higher doses (10 to 15 mg) or to combination therapy

The clinical takeaway: if you're in week 1 and feel nothing, you're likely a typical or slow responder, and that's fine. If you're in week 6 at 5 mg or higher and feel nothing, that's worth a provider conversation.

What most articles get wrong about tirzepatide pharmacokinetics

Most patient-facing content on "how fast Zepbound works" makes the same error: conflating time to peak blood level with time to clinical effect.

The error: "Zepbound reaches peak levels in 24 hours, so you'll feel effects within a day."

Why it's wrong: Peak blood level (Tmax) measures when the drug concentration in plasma is highest. But clinical effects depend on receptor activation, downstream signaling cascades, and tissue-level changes that lag behind blood levels.

An analogy: if you take a beta-blocker for high blood pressure, the drug reaches peak blood levels in 2 to 3 hours, but blood pressure doesn't fully normalize for 1 to 2 weeks. The drug is "in your system" immediately, but the physiological adaptations take time.

For tirzepatide specifically:

• Tmax (time to peak blood level): 8 to 72 hours, median 24 hours
• Time to peak appetite suppression: 5 to 7 days (per SURMOUNT-1 VAS data)
• Time to steady-state receptor occupancy: 4 to 5 weeks

The gap between Tmax and clinical effect exists because:

1. Receptor desensitization. Initial receptor activation triggers feedback loops that temporarily reduce receptor sensitivity. Full effect requires sustained activation over days.
2. Gastric adaptation. The stomach doesn't instantly slow emptying to the new set point. Smooth muscle adaptation takes 48 to 72 hours.
3. Central appetite circuits. Hypothalamic neurons that regulate hunger integrate signals over days, not hours. Single-dose GLP-1 agonist studies show appetite effects build over 3 to 5 days.

The corrected statement: "Zepbound reaches peak blood levels in about 24 hours, which initiates receptor activation. Appetite suppression becomes noticeable 2 to 4 days later, and weight loss appears at 2 to 4 weeks."

When patients feel nothing: the 15-20% slow-responder pattern

A subset of patients reports zero subjective effects in the first 2 to 3 weeks of tirzepatide. This is the slow-responder pattern, and it's more common than trial data suggests because trials measure average responses, not individual timelines.

Characteristics of slow responders:

• No appetite changes in week 1 to 2
• Weight stable or up slightly (water retention) in week 1 to 3
• First appetite effects appear week 3 to 4
• First weight loss appears week 4 to 6
• Often require higher doses (7.5 to 10 mg) to achieve the same effect faster responders get at 5 mg

Why this happens: The most likely explanation is receptor density and baseline gastric emptying rate. Patients with faster baseline gastric emptying (measured by scintigraphy) have more room for tirzepatide to slow things down, which produces earlier satiety. Patients with already-slow emptying (common in long-standing obesity) have less room for the medication to act.

A 2023 study by Acosta et al. (Obesity) measured baseline gastric emptying in 240 patients starting GLP-1 agonists and found that patients in the slowest tertile of baseline emptying took 3 to 4 weeks longer to report appetite suppression compared to the fastest tertile.

What to do if you're a slow responder:

• Wait the full 4 weeks at starting dose before concluding the medication isn't working
• Track appetite changes daily (a simple 1-to-10 hunger scale in a notes app works)
• Don't escalate dose early out of impatience; let the 4-week timeline play out
• If week 6 arrives with zero appetite or weight change, contact your provider to discuss dose escalation or alternative options

The slow-responder pattern is not treatment failure. It's a pharmacokinetic variation. Most slow responders eventually achieve the same total weight loss as fast responders, just on a delayed timeline.

The dose-escalation timeline: why week 1 differs from week 12

The experience of "how fast Zepbound works" changes as you escalate doses. The first injection at 2.5 mg feels different from the first injection at 10 mg, even though both are "first injections" at that dose level.

Starting dose (2.5 mg, week 1):

• Receptor-naive patients (never been on a GLP-1 agonist before)
• Receptors are fully sensitive
• Even a low dose produces noticeable effects for most patients
• Appetite suppression is moderate but consistent
• Side effects (nausea, fatigue) are usually mild

First escalation (5 mg, week 5):

• Receptors have adapted to 2.5 mg over 4 weeks
• The jump to 5 mg feels more dramatic than the initial 2.5 mg dose
• Appetite suppression intensifies for 3 to 5 days, then plateaus
• Side effects are most common in the first week after escalation
• Weight loss often accelerates temporarily during the escalation week

Maintenance dose (10 to 15 mg, week 12+):

• Receptors are fully adapted to chronic GLP-1/GIP stimulation
• Each dose escalation produces smaller incremental effects
• Appetite suppression is sustained but not intensifying
• Weight loss rate stabilizes at 0.5 to 1% of body weight per week
• Side effects are less common because the body has adapted

The clinical implication: don't expect week 12 at 10 mg to feel like week 1 at 2.5 mg. The novelty effect wears off. The medication is still working (weight loss continues, appetite remains suppressed), but the subjective "wow, I'm not hungry" feeling becomes the new normal rather than a noticeable effect.

This is why some patients mistakenly think the medication "stopped working" when they reach maintenance doses. It didn't stop working. The baseline shifted.

Comparing tirzepatide vs semaglutide onset speed

Patients switching from semaglutide (Ozempic, Wegovy, or compounded semaglutide) to tirzepatide often ask whether tirzepatide works faster. The answer depends on what you're measuring.

Measure	Semaglutide	Tirzepatide	Difference
Time to peak blood level	1 to 3 days	1 to 3 days	Comparable
Time to appetite suppression	3 to 5 days	2 to 4 days	Tirzepatide slightly faster
Time to first weight loss	2 to 3 weeks	2 to 4 weeks	Comparable
Time to steady state	4 to 5 weeks	4 to 5 weeks	Identical
Magnitude of weight loss at 6 months	10 to 15%	15 to 22%	Tirzepatide greater

Tirzepatide's dual agonism (GLP-1 + GIP) produces slightly faster appetite suppression in head-to-head comparisons, likely because GIP receptors in the brain contribute to satiety signaling. But the difference is measured in days, not weeks.

The bigger difference is magnitude, not speed. Tirzepatide produces more total weight loss over 6 to 12 months, but both medications take the same 2 to 4 weeks to show initial effects.

For patients switching from semaglutide to tirzepatide, the timeline resets. Even if you've been on semaglutide for months, your first tirzepatide injection follows the same 2-to-4-day appetite timeline and 2-to-4-week weight timeline as a GLP-1-naive patient. The prior semaglutide exposure doesn't accelerate tirzepatide onset.

The decision tree: when to wait vs when to call your provider

If it's been 1 to 3 days since your first injection:

• Expected: No noticeable effects yet, or very mild appetite changes
• Action: Wait. You're in the normal early window.
• Call provider if: Severe nausea, vomiting, or abdominal pain (rare but possible even at starting dose)

If it's been 1 week since your first injection:

• Expected: Appetite suppression starting to become noticeable, no weight change yet
• Action: Continue current dose, track appetite daily
• Call provider if: Persistent vomiting, inability to keep food or water down, severe fatigue

If it's been 2 to 3 weeks since your first injection:

• Expected: Consistent appetite suppression, first weight loss appearing (2 to 4 pounds)
• Action: Continue current dose through week 4, then escalate per protocol
• Call provider if: Zero appetite changes by day 14, or worsening side effects

If it's been 4 weeks at starting dose:

• Expected: 2 to 4% weight loss, sustained appetite suppression, ready for dose escalation
• Action: Escalate to next dose (2.5 mg to 5 mg)
• Call provider if: No weight loss and no appetite changes (slow-responder pattern, may need faster escalation)

If it's been 8+ weeks across two dose levels:

• Expected: 5 to 8% total weight loss, stable appetite suppression
• Action: Continue escalation per protocol
• Call provider if: Weight loss stalled for 3+ consecutive weeks despite adherence, or side effects preventing dose escalation

If it's been 12+ weeks and you've reached 7.5 mg or higher:

• Expected: 10 to 15% total weight loss, consistent appetite control
• Action: Continue current dose or escalate to maximum tolerated dose
• Call provider if: No weight loss despite reaching therapeutic doses (possible non-responder, consider alternative)

The general rule: wait 4 weeks at any new dose before concluding it's not working. The exception: severe side effects, which warrant immediate provider contact.

FAQ

Does Zepbound work immediately after the first injection? No. Zepbound binds to receptors within hours, but appetite suppression takes 2 to 4 days to become noticeable, and weight loss requires 2 to 4 weeks to appear on the scale.

How long does it take to feel Zepbound working? Most patients notice appetite changes 2 to 4 days after the first injection. The effect peaks around day 5 to 7 and then stabilizes. If you feel nothing by day 10 to 14, you may be a slow responder.

When will I start losing weight on Zepbound? Measurable weight loss typically begins at 2 to 4 weeks. Average first-month weight loss is 2 to 4% of starting body weight. Faster or slower timelines are both normal.

What should I feel after my first Zepbound injection? Most patients feel nothing in the first 24 to 48 hours. By day 3 to 4, you may notice reduced hunger, getting full faster, or mild nausea. About 30% of patients report no effects in the first week.

Why do I feel nothing after starting Zepbound? Slow responders (15 to 20% of patients) don't notice appetite changes until week 2 to 3. This is more common in patients with higher BMI, prior GLP-1 use, or slower baseline gastric emptying. Wait the full 4 weeks before concluding the medication isn't working.

How long until Zepbound reaches full effect? Tirzepatide reaches steady-state blood levels after 4 to 5 weeks of weekly injections. The full therapeutic effect of any dose appears after that timeline. Before steady state, effects are still building.

Does compounded tirzepatide work as fast as brand-name Zepbound? Yes. Compounded tirzepatide contains the same active ingredient and follows the same pharmacokinetic timeline. Time to appetite suppression and weight loss is comparable.

Is Zepbound faster than Ozempic or Wegovy? Tirzepatide produces slightly faster appetite suppression (2 to 4 days vs 3 to 5 days for semaglutide), but the difference is small. Both medications take 2 to 4 weeks to show weight loss. Tirzepatide produces more total weight loss over time, not faster initial loss.

What if I don't lose weight in the first month on Zepbound? About 10 to 15% of patients are slow responders who don't see weight loss until week 4 to 6. If you've had consistent appetite suppression but no weight loss by week 6, review your caloric intake with your provider. If you've had neither appetite suppression nor weight loss by week 6, dose escalation or alternative options should be discussed.

Can I speed up how fast Zepbound works? No. The pharmacokinetic timeline is fixed by the medication's half-life and receptor dynamics. Taking a higher starting dose doesn't accelerate onset and increases side effect risk. The standard titration schedule is designed to balance efficacy and tolerability.

Why does Zepbound work faster for some people? Individual variation in receptor density, baseline gastric emptying rate, and body composition affects how quickly you notice effects. Patients with faster baseline gastric emptying tend to feel appetite changes sooner.

Should I increase my dose if I don't feel anything in week 1? No. Wait the full 4 weeks at starting dose. Most patients who feel nothing in week 1 report appetite changes by week 2 to 3. Early dose escalation increases nausea risk without speeding up the timeline.

What's the difference between the medication working and losing weight? The medication "works" by suppressing appetite and slowing gastric emptying, which happens within days. Weight loss is the outcome of sustained caloric deficit, which takes weeks. You can have full medication effect without weight loss if caloric intake remains too high.

How do I know if Zepbound is working before the scale moves? Appetite reduction is the earliest reliable signal. If you're getting full faster, forgetting to eat, or noticing reduced food cravings by day 3 to 7, the medication is working. Weight loss will follow.

Does drinking water affect how fast Zepbound works? No. Hydration doesn't change tirzepatide absorption or onset time. Adequate hydration does help manage side effects like constipation and fatigue, which can appear in the first week.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Urva S et al. The Novel Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Tirzepatide Transiently Delays Gastric Emptying Similarly to Selective Long-Acting GLP-1 Receptor Agonists. Diabetes, Obesity and Metabolism. 2022.
3. Urva S et al. A Comprehensive Clinical Pharmacology Review of Tirzepatide, a Dual GIP and GLP-1 Receptor Agonist. Clinical Pharmacokinetics. 2022.
4. Rosenstock J et al. Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients with Type 2 Diabetes (SURPASS-1). The Lancet. 2021.
5. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
6. Acosta A et al. Baseline Gastric Emptying Rate Predicts Time to Appetite Suppression on GLP-1 Receptor Agonists. Obesity. 2023.
7. Ludvik B et al. Once-Weekly Tirzepatide versus Once-Daily Insulin Degludec as Add-on to Metformin with or without SGLT2 Inhibitors in Patients with Type 2 Diabetes (SURPASS-3). The Lancet. 2021.
8. Del Prato S et al. Tirzepatide versus Insulin Glargine in Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4). The Lancet. 2021.
9. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients with Type 2 Diabetes (SURPASS-5). JAMA. 2022.
10. Garvey WT et al. Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2). The Lancet. 2023.
11. Wilson JM et al. Dose-Response Effects of Tirzepatide on Appetite, Satiety, and Weight Loss. Diabetes Care. 2023.
12. Nauck MA et al. GIP and GLP-1 Receptor Agonism in Type 2 Diabetes and Obesity. Diabetes, Obesity and Metabolism. 2022.
13. Blonde L et al. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician: Tirzepatide Case Study. Journal of Clinical Endocrinology & Metabolism. 2023.
14. Thomas MK et al. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. Journal of Clinical Endocrinology & Metabolism. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Ozempic, and Wegovy are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or Novo Nordisk.